Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
Authors
Keywords
-
Journal
LANCET ONCOLOGY
Volume 24, Issue 1, Pages 77-90
Publisher
Elsevier BV
Online
2022-12-07
DOI
10.1016/s1470-2045(22)00694-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Standardized Investigational Ki-67 Immunohistochemistry Assay Used to Assess High-Risk Early Breast Cancer Patients in the monarchE Phase 3 Clinical Study Identifies a Population With Greater Risk of Disease Recurrence When Treated With Endocrine Therapy Alone
- (2022) Monika D. Polewski et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study
- (2022) H.S. Rugo et al. ANNALS OF ONCOLOGY
- A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer
- (2022) Kristin M Sheffield et al. Future Oncology
- FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer
- (2022) Melanie Royce et al. JOURNAL OF CLINICAL ONCOLOGY
- Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation
- (2022) Raquel Torres-Guzmán et al. Oncotarget
- Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
- (2021) Erica L Mayer et al. LANCET ONCOLOGY
- Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial
- (2021) Sibylle Loibl et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis
- (2021) Elizabeth M. Salvo et al. BREAST
- Letter to the Editor for ‘Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study’
- (2021) N. Harbeck et al. ANNALS OF ONCOLOGY
- Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
- (2021) N. Harbeck et al. ANNALS OF ONCOLOGY
- Adjuvant abemaciclib for high-risk breast cancer: the story continues
- (2021) L. Spring et al. ANNALS OF ONCOLOGY
- Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer
- (2021) Sibylle Loibl et al. BREAST
- Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2− Breast Cancer
- (2021) Mitch Dowsett et al. CLINICAL CANCER RESEARCH
- Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
- (2020) Stephen R. D. Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer
- (2019) Sara A. Hurvitz et al. CLINICAL CANCER RESEARCH
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
- (2018) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- (2017) Hongchao Pan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preclinical characterization of abemaciclib in hormone receptor positive breast cancer
- (2017) Raquel Torres-Guzmán et al. Oncotarget
- Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
- (2015) LANCET
- Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
- (2014) Lawrence M. Gelbert et al. INVESTIGATIONAL NEW DRUGS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started